Ab­b­Vie talks next steps as first Hu­mi­ra com­peti­tor makes it to mar­ket

In Ab­b­Vie’s first earn­ings call since Hu­mi­ra’s first biosim­i­lar came to mar­ket ear­li­er this year, CEO Rick Gon­za­lez tout­ed just over $58 bil­lion in rev­enue for the Big Phar­ma in 2022 — and laid out guid­ance for how the com­pa­ny will fare over the next two years, de­spite the loss of its Hu­mi­ra mo­nop­oly.

Af­ter tout­ing Ab­b­Vie’s more than dou­bling of its R&D bud­get, the CEO said the com­pa­ny is “well po­si­tioned to ab­sorb the im­pact from the Hu­mi­ra LOE and quick­ly re­turn to ro­bust sales growth in 2025.” The com­pa­ny al­so said it is ex­pect­ing to see Hu­mi­ra sales drop by 37% in 2023.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER